Furiex Pharmaceuticals FURX today announced it will receive a $5.0 million
milestone payment from the Menarini Group for the launch of Priligy in
the United Kingdom. Currently, Priligy is marketed for on-demand
treatment of premature ejaculation in over 20 countries in Europe, Asia
and Latin America, and is approved for that indication in over 60
countries worldwide.
In May 2012, Furiex entered into a license agreement with Menarini to
commercialize Priligy in Europe, most of Asia, Africa, Latin America and
the Middle East. Under the terms of the license agreement, Furiex is
eligible to up to $40.0 million in sales-based milestones, plus tiered
royalties ranging from the mid-teens
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in